Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06094192 · ClinicalTrials.gov registry record · NA

Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation

A NA study of Alzheimer Disease, sponsored by Boston University Charles River Campus.

Recruiting
Registry status
NA
Development phase
204
Enrollment target
1
Study location

NCT06094192 is a NA study of Alzheimer Disease that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 204 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06094192, a NA study of Alzheimer Disease, is actively recruiting participants, sponsored by Boston University Charles River Campus.

RECRUITING
Registry status
NA
Development phase
204 participants
Enrollment target
1
Study location

Study Summary

The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidate AD-related pathophysiology and set groundwork for the development of drug-free interventions for improving memory in AD and related dementias.

Conditions Studied

Interventions

  • DEVICE High definition transcranial electrical current stimulation

Study Locations (1)

Massachusetts

  • 677 Beacon St. Room 308 - Boston

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2023-12-20
Est. Completion 2028-05-31
Phase NA

What the Registry Record Tells You About NCT06094192

The ClinicalTrials.gov registry entry for NCT06094192 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which High definition transcranial electrical current stimulation is the first listed.

NCT06094192 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06094192 about?

NCT06094192 is a clinical study titled "Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation". The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidate AD-related pathophysiology and set groundwork for the deve...

What is the current status of trial NCT06094192?

This trial is currently recruiting. It is a NA study. The enrollment target is 204 participants. The study started on 2023-12-20. Estimated completion is 2028-05-31.

What conditions does trial NCT06094192 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT06094192?

The interventions under investigation include: High definition transcranial electrical current stimulation (DEVICE).

Who is sponsoring clinical trial NCT06094192?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06094192 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.